dr. rizvi on pd-1 and pd-l1 inhibitors in lung cancer
Published 10 years ago • 203 plays • Length 1:16Download video MP4
Download video MP3
Similar videos
-
1:15
dr. rizvi on pd-1 and pd-l1 inhibitors in lung cancer
-
0:51
dr. rizvi on pd-l1 as a biomarker for immunotherapy agents in lung cancer
-
48:15
immunotherapy for lung cancer: pd-1 and beyond, with naiyer rizvi
-
1:59
dr naiyer a. rizvi on pd-1 antibodies in lung cancer
-
7:22
pd-1 inhibition in lung cancer
-
1:57
targeting pd-1 and pd-l1 for lung cancer therapy
-
1:03
dr. rizvi discusses pembrolizumab for non-small cell lung cancer
-
1:23
dr. herbst on targeting pd-1 and pd-l1 in lung cancer
-
1:26
dr. rizvi on activity and toxicity of pembrolizumab for nsclc
-
1:29
dr. rizvi on utilizing molecular characteristics to inform treatment decisions in nsclc
-
0:50
dr. rizvi on pseudoprogression in lung cancer after immunotherapy
-
23:02
immunotherapy: moving beyond pd1 and pdl1 inhibitors
-
1:12
naiyer rizvi, md, describes the role of pd-l1 & tmb biomarkers in the treatment of lung cancer
-
1:34
dr. ribas on pd-1 and pd-l1 in cancer
-
1:13
dr. herbst on targeting pd-1 and pd-l1 in lung cancer
-
0:58
dr. chandra belani on selecting the best anti pd-l1 agent in lung cancer
-
1:52
efficacy of targeted therapies after pd-1/pd-l1 blockade in metastatic renal cell carcinoma
-
1:00
dr. nadler discusses role of pd-l1 in squamous nsclc
-
1:53
dr. brahmer on the role of pd-1 and pd-l1